NCT06049498Completed
Trial of Mongolian Medicine ZhenBao Pills for Upper-limb Dysfunction After Stroke
Efficacy and Safety of Mongolian Medicine ZhenBao Pills on Limb Function Recovery After Acute Ischemic Stroke: a Randomized Double-blinded Placebo-controlled Trial.
Source: ClinicalTrials.gov · Last updated 18 Jun 2026
Brief summary (registry, in English)
The trial was designed to test the hypothesis that treatment with Mongolian Medicine ZhenBao Pills has a positive effect on upper-limb motor recovery after acute ischemic stroke.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 216 (actual)
- First submitted
- 24 Jul 2023
- Start date
- 1 Jan 2024
- Primary completion date
- 31 Mar 2026
- Lead sponsor
- Dongzhimen Hospital, Beijing
- Diseases
- Stroke
- NCT number
- NCT06049498
What you commit to
- Study type: Interventional
- Participants enrolled: 216
- From 1 Jan 2024 to the primary completion date, 31 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Treatment within the last 3 months that may affect limb function, such as botulinum toxin injections or medications to improve limb motor function, etc.
Other illness
- Cranial CT or MRI findings of hemorrhage or other pathologic brain disorders, such as vascular malformations, tumors, abscesses, encephalitis, or other common non-ischemic brain diseases (e.g., multiple sclerosis).
- Coagulation disorders or history of systemic hemorrhage.
- Unable to complete the study due to mental illness, cognitive or emotional impairment.
- Suspected or known allergy to the components of the trial medication.
Lab values
- Chronic liver disease or elevated ALT, AST (greater than two times the upper limit of normal), renal insufficiency or elevated blood creatinine (greater than 1.5 times the upper limit of normal).
Other
- Life expectancy is less than 3 months.
- Pregnancy, breastfeeding or potential pregnancy.
- Within three months or currently participating in another investigational study.
- Other patients who, in the opinion of the investigator, are not suitable for participation of the study.
Who the study is looking for
- Adult subjects (male or female ≥18 years).
- The diagnosis of ischemic stroke should be met and the onset should be within 30 days.
- Patients with prestroke modified Rankin scale score 0-1.
- FAM-UE score of 20-57 at randomization.
- The patients and legal guardians signed informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Dongzhimen Hospital, Beijing University of Chinese Medicine Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.